Financials

v2.4.0.8
Consolidated Balance Sheets (USD $)
Jun. 30, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 11,103,596 $ 10,048,466
Short-term investments   305,538
Accounts receivable 392,696 458,391
Other current assets 477,339 344,386
Total current assets 11,973,631 11,156,781
Equipment, net 335,230 457,912
Restricted cash 2,843,413 2,921,724
Other long-term assets 74,663 159,224
Total assets 15,226,937 14,695,641
Current liabilities:    
Accounts payable 719,637 794,397
Accrued expenses 2,122,690 2,445,446
Deferred revenue 744,500 1,069,438
Accrued warrant liability 1,024,720 1,241,311
Current portion of notes payable 481,903 351,527
Current portion of capital lease obligation 50,827 83,634
Total current liabilities 5,144,277 5,985,753
Noncurrent portion of capital lease obligation   7,522
Long-term debt 3,634,034 7,121,388
Commitments and contingencies      
Total liabilities 8,778,311 13,114,663
Stockholders' equity:    
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2014 and December 31, 2013, respectively      
Common stock, $.005 par value; 160,000,000 shares authorized, 57,110,198 and 45,182,114 shares issued and outstanding as of June 30, 2014 and December 31, 2013, respectively 285,551 225,911
Additional paid-in capital 134,201,257 125,508,471
Accumulated other comprehensive income 236,497 307,339
Accumulated deficit (141,111,199) (135,564,666)
Total Cleveland BioLabs, Inc. stockholders' deficit (6,387,894) (9,522,945)
Noncontrolling interest in stockholders' equity 12,836,520 11,103,923
Total stockholders' equity 6,448,626 1,580,978
Total liabilities and stockholders' equity $ 15,226,937 $ 14,695,641
v2.4.0.8
Consolidated Statements of Operations (USD $)
3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Revenues:        
Grants and contracts $ 562,087 $ 1,613,262 $ 1,896,341 $ 2,980,734
Operating expenses:        
Research and development 2,324,223 5,373,029 4,763,996 10,704,644
General and administrative 2,250,368 3,016,851 4,663,911 6,500,223
Total operating expenses 4,574,591 8,389,880 9,427,907 17,204,867
Loss from operations (4,012,504) (6,776,618) (7,531,566) (14,224,133)
Other income (expense):        
Interest and other income (expense) (623,786) 47,809 (941,708) 127,765
Foreign exchange gain (loss) 92,594 46,776 (59,177) 74,910
Change in value of warrant liability 412,125 2,795,612 2,499,683 (652,111)
Total other income (expense) (119,067) 2,890,197 1,498,798 (449,436)
Net loss (4,131,571) (3,886,421) (6,032,768) (14,673,569)
Net loss attributable to noncontrolling interests 170,410 844,310 486,235 1,867,135
Net loss attributable to Cleveland BioLabs, Inc. $ (3,961,161) $ (3,042,111) $ (5,546,533) $ (12,806,434)
Net loss available to common stockholders per share of common stock, basic and diluted $ (0.08) $ (0.07) $ (0.11) $ (0.29)
Weighted average number of shares used in calculating net loss per share, basic and diluted 51,891,629 44,948,591 50,935,194 44,887,920
v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Cash flows from operating activities:    
Net loss $ (6,032,768) $ (14,673,569)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 107,958 189,840
Amortization 578,513  
Loss on equipment disposal 24,685  
Noncash compensation 182,617 1,122,857
Warrant issuance costs 171,116  
Change in value of warrant liability (2,499,683) 652,111
Changes in operating assets and liabilities:    
Accounts receivable 76,532 (1,155,910)
Other current assets (132,834) 303,845
Other long-term assets 15,879 (16,801)
Accounts payable (47,251) (322,004)
Deferred revenue (284,847) (661,811)
Accrued expenses 114,081 437,647
Net cash used in operating activities (7,726,002) (14,123,795)
Cash flows from investing activities:    
Sale of short-term investments 285,881 2,256,834
Purchase of equipment (10,803) (85,800)
Net cash provided by investing activities 275,078 2,171,034
Cash flows from financing activities:    
Issuance of common stock, net of offering costs 9,697,501  
Repayment of long-term debt (4,000,000)  
Noncontrolling interest capital contribution to Incuron, LLC 2,915,239  
Exercise of options   12,392
Repayment of capital lease obligation (40,329) (40,568)
Net cash provided by (used in) financing activities 8,572,411 (28,176)
Effect of exchange rate change on cash and equivalents (66,357) (425,749)
Increase (decrease) in cash and cash equivalents 1,055,130 (12,406,686)
Cash and cash equivalents at beginning of period 10,048,466 25,652,083
Cash and cash equivalents at end of period 11,103,596 13,245,397
Supplemental disclosure of cash flow information:    
Cash paid during the period for interest 360,642 12,714
Supplemental schedule of noncash financing activities:    
Noncash financing costs on common stock offering 50,505  
Noncash warrant issuance costs $ 15,993  
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue